Cytosorbents Statistics
Total Valuation
Cytosorbents has a market cap or net worth of $44.52 million. The enterprise value is $47.40 million.
| Market Cap | 44.52M |
| Enterprise Value | 47.40M |
Important Dates
The next estimated earnings date is Tuesday, May 7, 2024, after market close.
| Earnings Date | May 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Cytosorbents has 54.29 million shares outstanding. The number of shares has increased by 2.49% in one year.
| Shares Outstanding | 54.29M |
| Shares Change (YoY) | +2.49% |
| Shares Change (QoQ) | +4.91% |
| Owned by Insiders (%) | 9.38% |
| Owned by Institutions (%) | 38.04% |
| Float | 46.68M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 7.73 |
| PS Ratio | 1.24 |
| Forward PS | 1.10 |
| PB Ratio | 1.94 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.30 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.77, with a Debt / Equity ratio of 0.77.
| Current Ratio | 1.77 |
| Quick Ratio | 1.49 |
| Debt / Equity | 0.77 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -184.70 |
Financial Efficiency
Return on equity (ROE) is -120.20% and return on invested capital (ROIC) is -75.72%.
| Return on Equity (ROE) | -120.20% |
| Return on Assets (ROA) | -54.10% |
| Return on Capital (ROIC) | -75.72% |
| Revenue Per Employee | $195,427 |
| Profits Per Employee | -$153,266 |
| Employee Count | 186 |
| Asset Turnover | 0.69 |
| Inventory Turnover | 3.91 |
Taxes
| Income Tax | -813,739 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -69.63% in the last 52 weeks. The beta is 0.59, so Cytosorbents's price volatility has been lower than the market average.
| Beta (1Y) | 0.59 |
| 52-Week Price Change | -69.63% |
| 50-Day Moving Average | 0.93 |
| 200-Day Moving Average | 1.65 |
| Relative Strength Index (RSI) | 41.48 |
| Average Volume (30 Days) | 102,119 |
Short Selling Information
The latest short interest is 1.62 million, so 2.98% of the outstanding shares have been sold short.
| Short Interest | 1.62M |
| Short Previous Month | 1.67M |
| Short % of Shares Out | 2.98% |
| Short % of Float | 3.47% |
| Short Ratio (days to cover) | 15.95 |
Income Statement
In the last 12 months, Cytosorbents had revenue of $36.35 million and -$28.51 million in losses. Loss per share was -$0.64.
| Revenue | 36.35M |
| Gross Profit | 22.39M |
| Operating Income | -31.21M |
| Pretax Income | -29.32M |
| Net Income | -28.51M |
| EBITDA | -27.14M |
| EBIT | -29.16M |
| Loss Per Share | -$0.64 |
Balance Sheet
The company has $15.62 million in cash and $17.94 million in debt, giving a net cash position of -$2.32 million or -$0.04 per share.
| Cash & Cash Equivalents | 15.62M |
| Total Debt | 17.94M |
| Net Cash | -2.32M |
| Net Cash Per Share | -$0.04 |
| Equity / Book Value | 23.28M |
| Book Value Per Share | 0.43 |
| Working Capital | 11.16M |
Cash Flow
In the last 12 months, operating cash flow was -$21.66 million and capital expenditures -$538,115, giving a free cash flow of -$22.19 million.
| Operating Cash Flow | -21.66M |
| Capital Expenditures | -538,115 |
| Free Cash Flow | -22.19M |
| FCF Per Share | -$0.50 |
Margins
Gross margin is 61.60%, with operating and profit margins of -85.86% and -78.43%.
| Gross Margin | 61.60% |
| Operating Margin | -85.86% |
| Pretax Margin | -80.66% |
| Profit Margin | -78.43% |
| EBITDA Margin | -74.65% |
| EBIT Margin | -80.23% |
| FCF Margin | -61.06% |
Dividends & Yields
Cytosorbents does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.49% |
| Shareholder Yield | -2.49% |
| Earnings Yield | -63.25% |
| FCF Yield | -49.24% |
Analyst Forecast
The average price target for Cytosorbents is $2.50, which is 204.88% higher than the current price. The consensus rating is "Buy".
| Price Target | $2.50 |
| Price Target Difference | 204.88% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 26.22% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on December 5, 2014. It was a reverse split with a ratio of 1:25.
| Last Split Date | Dec 5, 2014 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
Cytosorbents has an Altman Z-Score of -7.4 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -7.4 |
| Piotroski F-Score | 4 |